Tritonix.ai

News / Taiwan / cnyes

健喬 (4114-TW) August Revenue Surges 50% to Record High

Health Technology · Pharmaceuticals: Major · cnyes · 2026-09-09

4114

Taiwanese pharmaceutical firm健喬 (4114-TW) reported a 49.88% year-on-year revenue increase for August, driven by strong sales in oncology and cardiovascular drugs.

What Happened

Revenue Growth:健喬 (4114-TW) announced August revenue of NT$754 million, marking a 49.88% year-on-year increase and the second-highest monthly performance in company history. Cumulative revenue for the first eight months of the year reached NT$5.096 billion, representing a 25.5% growth compared to the same period last year.

Product Performance: The company's core product lines showed strong momentum, with oncology, cardiovascular, and women's health medications growing by 43%, 48%, and 23% respectively. Additionally, nasal sprays and long-acting hormone therapies saw significant gains as they expanded their presence in major medical centers across Taiwan.

Market Expansion: The firm continues to deepen its footprint in digestive and women's health, with new drugs for chronic constipation and uterine fibroids now available in numerous medical institutions. Internationally, the company has secured distribution partnerships in Vietnam, with product launches anticipated by 2029.

Regulatory Milestone: The company's hormone production facility successfully passed the Japanese PMDA pharmaceutical compliance inspection in August. This achievement paves the way for future market entry into Japan and strengthens the company's overall international expansion strategy.

Read original

More in Health Technology

Shinhan Securities Trims Alteogen Price Target Following Clinical Trial Setback

Health Technology · yonhap_finance · 2026-09-08

Shinhan Securities lowered its target price for Alteogen to 520,000 KRW after a drug candidate in its Novartis licensing deal failed a Phase 3 trial.

196170

Healthcare Stocks Stumble as Novartis Trial Fails; Boeing Deliveries Lag

Health Technology · cnbc · 2026-09-08

Novartis shares dropped following a failed cardiovascular trial, weighing on the broader biotech sector, while Boeing reported a monthly decline in aircraft deliveries.

@CL.1, US10Y, .SPX, .IXIC, NVS, .DJI, AMGN, BA, NVS, LLY, XBI, @LCO26X, ABBV, GILD, NVDA, CHWY, SIG

Joyo Pharm Reports 50% Revenue Surge in August

Health Technology · economic_daily · 2026-09-08

Joyo Pharmaceutical announced a 50% year-over-year revenue increase for August, driven by strong sales in oncology, cardiovascular, and women's health products.

4114

Latest in Taiwan

Emerging Markets Show Resilience as Local Investors Absorb Foreign Selling, AI Remains Key Catalyst

Electronic Technology · economic_daily · 2026-09-09

Despite recent foreign outflows from emerging markets like Taiwan and Korea, local investors are stepping in, signaling confidence as AI spending continues to drive growth.

Fu-Chun Shares Surge to Complete Ex-Dividend; Institutional Buying Drives Rally

Electronic Technology · economic_daily · 2026-09-09

Fiberglass fabric maker Fu-Chun successfully completed its ex-dividend rally today, supported by strong institutional buying and optimistic AI server demand.

1303, 1802, 1815, 5340, 5475

Analysts Raise ASPEED Price Target Amid Strong Server Market Outlook

Electronic Technology · economic_daily · 2026-09-09

ASPEED is seeing improved supply chain conditions and robust server demand, leading analysts to upgrade profit forecasts and price targets for the company.

5274

Taiwan's Unsold New Housing Inventory Surges to 112,500 Units, Led by Taoyuan and Kaohsiung

Finance · cnyes · 2026-09-09

Taiwan's unsold new housing stock has jumped over 60% in five years to 112,500 units, with Taoyuan and Kaohsiung facing the most significant inventory pressure.